**Supplement Table S1.** Baseline clinical, laboratory, and procedural characteristics in the total study population

| Variables                                | Total population (n = 6448) | Normoglycemia (n = 1749) | Prediabetes (n = 2103) | T2DM (n = 2596) | p value  |
|------------------------------------------|-----------------------------|--------------------------|------------------------|-----------------|----------|
| Men, n (%)                               |                             | 1419 (81.1)              | 1619 (77.0)            | 1921 (74.0)     | <0.001   |
| Age, years                               |                             | 60.3 ± 13.1              | 62.7 ± 12.9            | 63.1 ± 11.8     | <0.001   |
| LVEF, %                                  |                             | 51.3 ± 10.6              | 51.1 ± 11.2            | 49.9 ± 11.2     | <0.001   |
| BMI, kg/m²                               |                             | 23.8 ± 3.2               | 24.2 ± 3.3             | 24.5 ± 3.2      | <0.001   |
| Waist circumference, cm                  |                             | 85.5 ± 8.3               | 86.8 ± 9.7             | 88.0 ± 9.1      | <0.001   |
| SBP, mmHg                                |                             | 128.3 ± 27.8             | 126.0 ± 27.8           | 128.0 ± 28.9    | 0.019    |
| DBP, mmHg                                |                             | 79.5 ± 17.0              | 77.7 ± 16.9            | 77.7 ± 17.2     | 0.001    |
| Cardiogenic shock, n (%)                 |                             | 94 (5.4)                 | 127 (6.0)              | 171 (6.6)       | 0.259    |
| CPR on admission, n (%)                  |                             | 120 (6.9)                | 134 (6.4)              | 141 (5.4)       | 0.133    |
| Hypertension, n (%)                      |                             | 667 (37.9)               | 855 (40.6)             | 1480 (57.0)     | <0.001   |
| Dyslipidemia, n (%)                      |                             | 146 (8.3)                | 229 (10.9)             | 348 (13.4)      | <0.001   |
| Previous MI, n (%)                       |                             | 49 (2.8)                 | 49 (2.3)               | 97 (3.7)        | 0.016    |
| Previous PCI, n (%)                      |                             | 59 (3.4)                 | 83 (3.9)               | 148 (5.7)       | <0.001   |
| Previous CABG, n (%)                     |                             | 4 (0.2)                  | 2 (0.1)                | 14 (0.5)        | 0.019    |
| Previous CVA, n (%)                      |                             | 68 (3.9)                 | 85 (4.0)               | 169 (6.5)       | <0.001   |
| Previous HF, n (%)                       |                             | 6 (0.3)                  | 19 (0.9)               | 29 (1.1)        | 0.021    |
| Atrial fibrillation, n (%)               |                             | 36 (2.1)                 | 44 (2.1)               | 54 (2.1)        | 0.997    |
| Current smokers, n (%)                   |                             | 848 (48.5)               | 1060 (50.4)            | 1133 (43.6)     | <0.001   |
| Peak CK-MB, mg/dL                        |                             | 181.5 ± 242.6            | 188.4 ± 212.0          | 151.0 ± 163.0   | <0.001   |
| Peak Troponin-I, ng/mL                   |                             | 67.8 ± 100.2             | 67.6 ± 156.2           | 70.8 ± 195.0    | 0.799    |
| Fasting glucose, mg/dL                   |                             | 144.8 ± 49.6             | 155.8 ± 49.5           | 235.1 ± 97.1    | <0.001   |
| Hemoglobin A1c (%)                       |                             | 5.3 ± 0.4                | 6.0 ± 0.2              | 7.9 ± 3.1       | <0.001   |
| NT-ProBNP (pg/mL)                        |                             | 1122.4 ± 3703.2          | 1143.7 ± 2912.3        | 1862.5 ± 4861.3 | <0.001   |
| Hs-CRP (mg/dL)                           |                             | 6.1 ± 32.8               | 8.0 ± 40.7             | 11.4 ± 48.9     | 0.001    |
| Metric                              | Mean ± SD       | Median ± SD     | P Value |
|------------------------------------|-----------------|-----------------|---------|
| Serum creatinine (mg/L)            | 1.01 ± 1.00     | 1.06 ± 1.70     | 1.11 ± 0.90 | 0.032 |
| eGFR, mL/min/1.73m²                | 89.2 ± 30.9     | 87.7 ± 41.6     | 84.9 ± 126.9 | 0.001 |
| Total cholesterol, mg/dL           | 180.3 ± 40.2    | 190.5 ± 32.6    | 179.9 ± 46.5 | <0.001 |
| Triglyceride, mg/L                 | 120.0 ± 108.7   | 136.5 ± 132.7   | 151.6 ± 126.9 | <0.001 |
| HDL cholesterol, mg/L              | 44.4 ± 15.0     | 43.9 ± 17.3     | 41.8 ± 14.1  | <0.001 |
| LDL cholesterol, mg/L              | 113.6 ± 35.4    | 122.7 ± 46.9    | 111.1 ± 38.7 | <0.001 |
| Diabetes management                |                 |                 |         |
| Diet                               |                 |                 | 234 (9.0) |       |
| Oral agent                         |                 |                 | 1545 (59.5) |       |
| Insulin                            |                 |                 | 127 (4.9)  |       |
| Untreated                          |                 |                 | 690 (26.6) |       |
| Discharge medications, n (%)       |                 |                 |         |
| Aspirin, n (%)                     | 1698 (97.1)     | 2022 (96.3)     | 2492 (96.0) | 0.146 |
| Clopidogrel, n (%)                 | 1398 (79.9)     | 1805 (85.8)     | 2196 (84.6) | <0.001 |
| Ticagrelor, n (%)                  | 211 (12.1)      | 174 (8.3)       | 217 (8.4)  | <0.001 |
| Prasugrel, n (%)                   | 119 (6.8)       | 108 (5.1)       | 140 (5.4)  | 0.059 |
| Cilostazole, n (%)                 | 258 (14.8)      | 388 (18.4)      | 503 (19.4) | <0.001 |
| BBs, n (%)                         | 1464 (83.7)     | 1760 (83.7)     | 2170 (83.6) | 0.993 |
| ACEIs, n (%)                       | 1062 (60.7)     | 1208 (57.4)     | 1386 (53.4) | <0.001 |
| ARBs, n (%)                        | 384 (22.0)      | 472 (22.4)      | 693 (26.7) | <0.001 |
| CCBs, n (%)                        | 57 (3.3)        | 65 (3.1)        | 110 (4.2)  | 0.074 |
| Lipid-lowering agents              | 1578 (90.2)     | 1870 (88.9)     | 2226 (85.7) | <0.001 |
| IRA                                |                 |                 |         |
| Left main, n (%)                   | 26 (1.5)        | 19 (0.9)        | 32 (1.2)  | 0.246 |
| LAD, n (%)                         | 967 (55.3)      | 1140 (54.2)     | 1288 (49.6) | <0.001 |
| LCx, n (%)                         | 159 (9.1)       | 186 (8.8)       | 225 (8.7)  | 0.890 |
| RCA, n (%)                         | 597 (34.1)      | 758 (36.0)      | 1051 (40.5) | <0.001 |
| Treated vessel                     |                 |                 |         |
| Left main, n (%)                   | 39 (2.2)        | 33 (1.6)        | 46 (1.8)  | 0.301 |
| LAD, n (%)                         | 1074 (61.4)     | 1286 (61.2)     | 1529 (58.9) | 0.160 |
| Parameter                                      | LCx, n (%) | RCA, n (%) | ACC/AHA lesion type | Extent of CAD | Symptom-to-balloon time (min) | Door-to-balloon time (min) | Culprit-only PCI | Multivessel PCI | Completeness of PCI | Stent diameter (mm) | Stent length (mm) |
|-----------------------------------------------|------------|------------|--------------------|---------------|------------------------------|----------------------------|------------------|------------------|---------------------|---------------------|---------------------|
| LCx, n (%)                                    | 268 (15.3) | 336 (16.0) | 444 (17.1)         | 0.272         |                              |                            |                  |                  |                     | 3.20 ± 0.42         | 26.9 ± 10.2         |
| RCA, n (%)                                    | 670 (38.3) | 860 (40.9) | 1198               | <0.001        |                              |                            |                  |                  |                     | 3.19 ± 0.41         | 26.5 ± 10.4         |
| Extent of CAD                                 |            |            |                    |               |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| 1-vessel disease, n (%)                       | 1029 (58.8)| 1180 (56.1)| 1223 (47.1)        | <0.001        |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| 2-vessel disease, n (%)                       | 493 (28.2) | 623 (29.6) | 813 (31.3)         | 0.082         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| ≥3-vessel disease, n (%)                      | 227 (13.0) | 300 (14.3) | 560 (21.6)         | <0.001        |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| ACC/AHA lesion type                           |            |            |                    |               |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Type B1, n (%)                                | 225 (12.9) | 293 (13.9) | 322 (12.4)         | 0.293         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Type B2, n (%)                                | 566 (32.4) | 633 (30.1) | 830 (32.0)         | 0.249         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Type C, n (%)                                 | 828 (47.3) | 993 (47.2) | 1258 (48.5)        | 0.644         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| IVUS, n (%)                                   | 326 (18.6) | 449 (21.4) | 503 (19.4)         | 0.084         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| OCT, n (%)                                    | 4 (0.2)    | 8 (0.4)    | 9 (0.3)            | 0.692         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| FFR, n (%)                                    | 12 (0.8)   | 22 (1.0)   | 24 (0.9)           | 0.826         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Drug-eluting stents                           |            |            |                    |               |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| ZES, n (%)                                    | 561 (32.1) | 749 (35.6) | 938 (36.1)         | 0.015         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| EES, n (%)                                    | 899 (51.4) | 1089 (51.8)| 1288 (49.6)        | 0.283         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| BES, n (%)                                    | 272 (15.6) | 249 (11.8) | 322 (12.4)         | 0.001         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Others, n (%)                                 | 43 (2.5)   | 56 (2.7)   | 86 (3.3)           | 0.201         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Symptom-to-balloon time (min)                 | 185 (123-288)| 188 (130-302)| 186 (128-297)     | 0.275         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Door-to-balloon time (min)                    | 60.0 (46.0-77.0)| 61.0 (45.0-80.0)| 60.5 (45.0-79.0) | 0.722         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Culprit-only PCI                              | 1068 (61.1)| 1111 (52.8)| 1418 (54.6)        | <0.001        |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Multivessel PCI                               | 681 (38.9) | 992 (47.2) | 1178 (45.4)        | <0.001        |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| PCI for non-IRA                               |            |            |                    |               |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| During index PCI, n (%)                       | 437 (64.2) | 648 (65.3) | 759 (64.4)         | 0.821         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Before discharge, n (%)                       | 244 (35.8) | 344 (34.7) | 419 (35.6)         | 0.821         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Completeness of PCI                           |            |            |                    |               |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| CR, n (%)                                     | 469 (68.9) | 707 (71.3) | 821 (69.7)         | 0.537         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| IR, n (%)                                     | 212 (31.1) | 285 (28.7) | 357 (30.3)         | 0.537         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Stent diameter (mm)                           | 3.20 ± 0.42| 3.19 ± 0.41| 3.16 ± 0.42        | <0.001        |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Stent length (mm)                             | 26.9 ± 10.2| 26.5 ± 10.4| 27.0 ± 10.7        | 0.212         |                              |                            |                  |                  |                     | 3.16 ± 0.42         | 27.0 ± 10.7         |
| Number of stent | 1.34 ± 0.63 | 1.40 ± 0.71 | 1.45 ± 0.75 | <0.001 |

Values are means ± SD or numbers and percentages or median (quartile 1- quartile 3). The p values for continuous data obtained from the analysis of variance. The p values for categorical data from chi-square or Fisher’s exact test.

T2DM: type 2 diabetes mellitus; LVEF: left ventricular ejection fraction; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CVA: cerebrovascular accident; HF: heart failure; CK-MB: creatine kinase myocardial band; NT-ProBNP: N-terminal pro-brain natriuretic peptide; Hs-CRP: high sensitivity C-reactive protein; eGFR: estimated glomerular filtration rate; HDL: high-density lipoprotein; LDL: low-density lipoprotein; BBs: β-blockers; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CCBs: calcium channel blockers; IRA: infarct-related artery; LAD: left anterior descending coronary artery; LCx: left circumflex coronary artery; RCA: right coronary artery; CAD: coronary artery disease; ACC/AHA: American College of Cardiology/American Heart Association; IVUS: intravascular ultrasound; OCT: optical coherence tomography; FFR: fractional flow reserve; ZES: zotarolimus-eluting stent; EES: everolimus-eluting stent; BES: biolimus-eluting stents; CR: complete revascularization; IR: incomplete revascularization.